Please use this identifier to cite or link to this item: https://doi.org/10.1016/B978-0-12-372550-9.00017-1
Title: Systems Biology in Drug Discovery: Using Predictive Biomedicine to Guide Development Choices for Novel Agents in Cancer
Authors: Tucker-Kellogg, G. 
Aggarwal, A.
Blanchard, K.
Gaynor, R.
Issue Date: 2010
Citation: Tucker-Kellogg, G.,Aggarwal, A.,Blanchard, K.,Gaynor, R. (2010). Systems Biology in Drug Discovery: Using Predictive Biomedicine to Guide Development Choices for Novel Agents in Cancer. Systems Biomedicine : 399-414. ScholarBank@NUS Repository. https://doi.org/10.1016/B978-0-12-372550-9.00017-1
Abstract: This chapter discusses systems-based approaches to translational medicine. This is made possible by the convergent acceleration of several disciplines-computational, post-genomic platform and biomedical sciences-working together to offer a more complete picture of the complexities of disease and disease treatment. Systems-based approaches offer an increasingly less biased set of platforms with which to observe the phenomenal diversity of cancers and conduct experiments in a wider range of more clinically relevant models. This chapter also describes how systems approaches for predictive biomedicine-integrating discovery and clinical data-can be applied to identify novel targets, predictive biomarkers of response to agents in development and targeted use of drug combinations. The objective of these approaches is for new agents, the development of which is guided by predictive biomedicine to improve outcomes for individual cancer patients. Some more recently approved agents, such as sorafenib, intentionally target several members of signaling cascades dysregulated in tumors, taking advantage of the multitargeted nature of many kinase inhibitors. There has also been a phenomenal explosion in the generation of experimental data in the wake of the human genome project. Rapid advances in computational processing power, data storage, modeling, and analysis have become available to make such data interpretable. The convergence of these three trends-targeted therapies in cancer, post-genomic system-wide experimentation platforms, and unprecedented advances in information technology-lays the foundation for the application of systems biology to drug discovery in cancer. © 2010 Elsevier Inc. All rights reserved.
Source Title: Systems Biomedicine
URI: http://scholarbank.nus.edu.sg/handle/10635/102369
ISBN: 9780123725509
DOI: 10.1016/B978-0-12-372550-9.00017-1
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

1
checked on Jan 12, 2020

Page view(s)

167
checked on Jan 18, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.